CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法在治疗多种类型的复发/难治性（R/R）B细胞恶性肿瘤患者中已取得显著进展，包括弥漫性大B细胞淋巴瘤（DLBCL）、B细胞急性淋巴细胞白血病（B-ALL）、滤泡性淋巴瘤（FL）、套细胞淋巴瘤（MCL）和多发性骨髓瘤（MM）。然而，该疗法在对抗T细胞肿瘤方面面临严重障碍。R/R T细胞恶性肿瘤通常与不良临床结局相关，且可用的有效治疗方法非常有限。与B细胞恶性肿瘤相比，T细胞恶性肿瘤的CAR-T 治疗具有独特的障碍。自相残杀、T细胞再生障碍以及生产自体CAR-T 时产品被恶性T细胞污染，是T细胞恶性肿瘤中CAR-T 治疗最重要的挑战，需要进行深入研究。在此，我们重点介绍为解决这些缺陷所做的临床前和临床努力，并综述可改善T细胞恶性肿瘤CAR-T 治疗的其他有效策略。
Chimeric antigen receptor T-cell (CAR-T) therapy has been prosperous in the treatment of patients with various types of relapsed/refractory (R/R) B-cell malignancies including diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and multiple myeloma (MM).
However, this type of therapy has faced serious hindrances in combating T-cell neoplasms. R/R T-cell malignancies are generally associated with poor clinical outcomes, and the available effective treatment approaches are very limited.
CAR-T therapy of T-cell malignancies has unique impediments in comparison with that of B-cell malignancies. Fratricide, T-cell aplasia, and product contamination with malignant T cells when producing autologous CAR-Ts are the most important challenges of CAR-T therapy in T-cell malignancies necessitating in-depth investigations.
Herein, we highlight the preclinical and clinical efforts made for addressing these drawbacks and also review additional potent stratagems that could improve CAR-T therapy in T-cell malignancies.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
